SynthesisTheranostics2025

Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis.

Gaia Ninatti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.